AIG onco 1 - AIGEN Sciences
Alternative Names: AIG-onco-1Latest Information Update: 08 Feb 2024
At a glance
- Originator AIGEN Sciences
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer; Pancreatic cancer
Most Recent Events
- 02 Feb 2024 Early research in Colorectal cancer in South Korea (unspecified route) (AIGEN Sciences pipeline, February 2024)
- 02 Feb 2024 Early research in Pancreatic cancer in South Korea (unspecified route) (AIGEN Sciences pipeline, February 2024)
- 02 Feb 2024 AIGEN Sciences plans to file IND application in Pancreatic and Colon cancer in 2024 (AIGEN Sciences pipeline, February 2024)